38 results
424B5
MAIA
MAIA Biotechnology Inc
14 Feb 24
Prospectus supplement for primary offering
5:18pm
Research Ethics Committee. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia. In December 2022 … the Phase 2 study in Australia was approved on March 1, 2022, by the Australian Regulatory Agency—Bellberry Human Research Ethics Committee. In July 2022
424B5
MAIA
MAIA Biotechnology Inc
17 Nov 23
Prospectus supplement for primary offering
9:06am
—Bellberry Human Research Ethics Committee. In July 2022, the first patient was administered with THIO in our Phase 2 human trial (THIO-101) in Australia … study in Australia was approved on March 1, 2022, by the Australian Regulatory Agency—Bellberry Human Research Ethics Committee. In July 2022
424B5
uhkqw r0ymlf98u9v
1 Sep 23
Prospectus supplement for primary offering
4:30pm
S-3
l4l 5wnohsi9ashbexd
14 Aug 23
Shelf registration
6:05pm
DRS
m5li874yeq
1 Jun 23
Draft registration statement
12:00am
424B4
1o8o4kn5
25 Apr 23
Prospectus supplement with pricing info
7:45pm
DEF 14A
jqhd3ok8hpv1 r05
19 Apr 23
Definitive proxy
4:06pm
DRS
14mbvoaljzzwi 3dbb5b
23 Dec 22
Draft registration statement
12:00am
8-K
kj3vvhzjrg
21 Sep 22
Departure of Directors or Certain Officers
4:15pm